Contineum Therapeutics (CTNM) Equity Average (2023 - 2026)

Contineum Therapeutics' Equity Average history runs 4 years deep, the most recent figure standing at $255.5 million for Q1 2026.

• In Q1 2026, Equity Average rose 33.49% year-over-year to $255.5 million; the TTM figure through Mar 2026 stood at $255.5 million (up 33.49% YoY), while the FY2025 annual figure was $229.5 million, up 252.77% from the prior year.
• Equity Average was $255.5 million for Q1 2026 at Contineum Therapeutics, up from $220.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $255.5 million in Q1 2026 to a low of -$76.4 million in Q2 2023.
• Historically, Equity Average has averaged $103.3 million across 4 years, with a median of $177.0 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Equity Average soared 466.91% in 2024, then fell 17.74% in 2025.
• A 4-year view of Equity Average shows it stood at -$64.5 million in 2023, then soared by 416.31% to $204.1 million in 2024, then increased by 8.12% to $220.7 million in 2025, then grew by 15.76% to $255.5 million in 2026.
• The last three Equity Average figures came in at $255.5 million (Q1 2026), $220.7 million (Q4 2025), and $175.9 million (Q3 2025), per Business Quant data.